GoingToMeet

With over 130 products on the market worth $50bn, biologicals and biopharmaceuticals remain the fastest growing segment amongst novel pharmaceutical entities today1, 2. Mirroring this trend, the market for lyophilising these compounds, currently approaching 200 million units3, is set to continue its year-on-year double digit growth.

Without lyophilisation, 60% of biotherapeutics including recombinant proteins, plasma, vaccines and antibodies could not be commercially available3. Freeze-drying has become increasingly efficient in recent years, easier to use, more cost-effective and extremely accurate. It imparts higher stability, broader temperature tolerance, and longer shelf life to pharmaceutical formulations unstable in aqueous solution4.

Although the commonest way to ensure longevity and stability for complex molecules, lyophilisation however remains costly, complex and facility-intensive. Fine-tuning cycle parameters and trial-and-error experimentation also means the procedure remains as much of an art as a science5. As reducing development time becomes increasingly important in today’s economic climate, a rational, empirical approach to cycle design can save you time and money, especially when upscaling. More importantly, a robust lyophilization cycle will guarantee a safe and effective product.

Mastering these complex and inter-related requirements is no mean feat and Visiongain’s 4th Lyophilisation conference provides distilled intelligence on formulation and process development for biopharmaceuticals. With a workshop and sessions led by experts, you will gain a thorough understanding to provide the best outcome for your organisation. Case studies from industry will offer strategic insights to help you optimise key input and output parameters, and troubleshoot challenges with temperature-sensitive moieties or solid proteins.